Key drivers for market penetration of biosimilars in Europe.

Key drivers for market penetration of biosimilars in Europe.

Item
http://www.wikidata.org/entity/Q37669625
Pricing and Reimbursement of Biosimilars in Central and Eastern European CountriesSupply-side and demand-side policies for biosimilars: an overview in 10 European member states.Policies for biosimilar uptake in Europe: An overview.A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
P2860

Key drivers for market penetration of biosimilars in Europe.

Item
http://www.wikidata.org/entity/Q37669625
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Key drivers for market penetration of biosimilars in Europe.
@en
Key drivers for market penetration of biosimilars in Europe.
@nl
type
label
Key drivers for market penetration of biosimilars in Europe.
@en
Key drivers for market penetration of biosimilars in Europe.
@nl
prefLabel
Key drivers for market penetration of biosimilars in Europe.
@en
Key drivers for market penetration of biosimilars in Europe.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Key drivers for market penetration of biosimilars in Europe
@en
P2093
P2860
P304
P31
P356
10.1080/20016689.2016.1272308
P433
P478
P50
P577
P698
P932